AHA 2016 | NEW ORLEANS — More information continues to accumulate about a novel cholesterol drug known as inclisiran that uses RNA interference technology to inhibit the synthesis of PCSK9 in the liver. Read More >>>

Keywords: AHA Annual Scientific Sessions, AHA16

< Back to Listings